AstraZeneca said on Tuesday that it expects both profit and revenue to grow in 2026, supported by solid demand for its cancer treatments and a growing portfolio of newer medicines. The forecast reflects the company’s continued expansion efforts in its two largest markets, the United States and China.
The outlook aligns with long-term ambitions set by chief executive Pascal Soriot, who is guiding the company toward its goal of reaching $80 billion in annual revenue by 2030. The strategy focuses on launching new therapies and increasing investment, even as U.S. tariff rules and healthcare policies remain in flux.
AstraZeneca has recently made significant investments to strengthen its presence in the U.S. and China. These include a $50 billion manufacturing investment in the United States last year, a listing on the New York Stock Exchange, and a further $15 billion investment in China this year, following earlier challenges in the region.
The UK’s most valuable listed company expects total revenue in 2026 to rise by a mid-to-high single-digit percentage at constant exchange rates. Core profit is projected to grow by a low double-digit percentage over the same period.
In 2025, AstraZeneca reported an 8% increase in sales and an 11% rise in profit. The company had previously guided for revenue growth in the high single digits and core earnings growth in the low double digits.
For the three months ending December 31, core earnings reached $2.12 per share, while total revenue increased 2% to $15.50 billion. Both figures matched market expectations, according to company-compiled analyst consensus data.
Sales of AstraZeneca’s oncology medicines climbed 20% during the quarter to $7.03 billion. In contrast, revenue from cardiovascular treatments declined 6% to $3.05 billion, partly reflecting increased competition from generic alternatives.
